nemolizumab
galderma
['olympia 2', 'nemolizumab', 'derm', 'galderma']
galderma presented p-iii trial (olympia 2) results of nemolizumab for the treatment of prurigo nodularis at wcd 2023 #clinicaltrials 
Real-time summarized News in 3 shots from pharma, biotech, medtech, digital health and life sciences industry readable in 60 seconds